Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

Boron-containing compounds (BCC) have emerged as important pharmacophores. To date,
five BCC drugs (including boronic acids and boroles) have been approved by the FDA for …

Pediatric hepatoblastoma is the most common primary liver cancer in infants and children.
Studies of hepatoblastoma that focus exclusively on tumor cells demonstrate sparse somatic …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

Abstract b-AP15, a potent and selective inhibitor of the ubiquitin-specific peptidase 14
(USP14), displays in vitro and in vivo antitumor abilities on some types of cancer cells …

Many cellular events are driven by changes in protein expression, measurable by mass
spectrometry or antibody-based assays. However, using conventional technology, the …

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly
important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy …

Abstract Development of selective or dual proteasome subunit inhibitors based on syringolin
B as a scaffold is described. We focused our efforts on a structure–activity relationship study …

Asialoglycoprotein receptors (ASGPRs) are highly expressed on hepatocytes and have
been used for liver-targeted delivery and hepatocellular carcinoma (HCC) therapy …

Simple Summary Proteasome inhibitors are currently used in the treatment of certain blood
cancers, and clinical trials to treat solid tumors, including liver cancer, have also been …